about
Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkheadA PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis.Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumorsPhosphoinositide 3-kinase controls early and late events in mammalian cell divisionPhosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entryp85β phosphoinositide 3-kinase subunit regulates tumor progressionPhosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation.Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase.Specific function of phosphoinositide 3-kinase beta in the control of DNA replication.The N-Terminal Phosphorylation of RB by p38 Bypasses Its Inactivation by CDKs and Prevents Proliferation in Cancer Cells.Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors.Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing.PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.A cascade involving p85, Cdc42 and septin 2 regulates cytokinesis.
P50
Q28506168-9B73636B-2921-4EC6-9C76-5BE6DFB98C4AQ30478155-108333C4-DE66-47BF-973A-D9D6201FC78FQ34375736-B2ACA7C6-F3A6-44C6-8B82-B1E75DA56A40Q34410971-A3745736-ECF9-47B9-B351-D67E35AD43ECQ35131676-3F08593C-5527-48B4-BA7E-30C0521A2212Q36094306-7C17A45D-1388-4FAB-AAC9-D784C1A66DA1Q36229227-9BC58FD3-43D3-4225-8C5C-5C597F600DE3Q36540331-A21865D8-9B31-4D92-BA34-161700E44544Q37183054-FF7210E4-B565-485B-9E35-A88BCF01EFD1Q38745441-F94D6BD6-B236-4C24-880B-B7109F68F85AQ38803515-C3499934-11EB-44BE-B0F6-A5C6C858F400Q39098321-8A6508E0-8710-4CB2-BA13-CC3B9F2A941EQ42118139-4D805562-C4A1-4309-9E05-5062419D3651Q44581657-3CA0462E-E73B-4D92-8AFD-311834B0A09AQ45051974-A3631D95-66C6-4D60-A67D-4CF4A68DA589Q53190178-33ACBD73-F09A-4D9E-A13F-8BB3286F4D4CQ53564823-8FC9CA43-74E1-4B18-AD0D-0BD7921E92EF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miriam Marqués
@ast
Miriam Marqués
@en
Miriam Marqués
@es
Miriam Marqués
@nl
Miriam Marqués
@sl
type
label
Miriam Marqués
@ast
Miriam Marqués
@en
Miriam Marqués
@es
Miriam Marqués
@nl
Miriam Marqués
@sl
prefLabel
Miriam Marqués
@ast
Miriam Marqués
@en
Miriam Marqués
@es
Miriam Marqués
@nl
Miriam Marqués
@sl
P106
P21
P31
P496
0000-0003-1550-3033